Sutro Biopharma Inc. (STRO) has released updated findings from its ongoing Phase 1b clinical trial investigating the combination of luveltamab tazevibulin (luvelta) and bevacizumab in treating epithelial ovarian cancer.According to the data, the duo of luvelta and bevacizumab has shown promising antitumor activity in patients with advanced ovarian cancer, regardless of Folate Receptor-Alpha expression. This includes patients who lack Folate Receptor-Alpha expression and those previously treated with bevacizumab. The combined therapy achieved an overall response rate of 35%. These preliminary results suggest that this treatment approach might provide a viable option for epithelial ovarian cancer patients without the need for biomarker-based selection.The company highlighted that administering 4.3 mg/kg of luveltamab tazevibulin with the standard 15 mg/kg dose of bevacizumab every three weeks resulted in a 56% objective response rate among patients with late-stage ovarian cancer. This dosage regimen has been selected as the recommended Phase 2 dose (RP2D).The material has been provided by InstaForex Company – www.instaforex.com
- Czech Retail Sales Growth Accelerates in August, Reaching 5.30% - October 8, 2024
- Czech Unemployment Rate Sees Slight Uptick in September - October 8, 2024
- France Sees Rise in Imports: August Figures Show a Notable Increase - October 8, 2024
